Genmab — Oktober 2022
-
Dejligt vi må komme indenfor
-
Enig, eller da nogen i juni, troede den ville falde yderligere fra 1850
-
Saxo TA viser kileformation med modstand i 2866 fra g.d. Ligner den får en øretæve efter blot 24 timer
-
Vitus - du springer bare TA kommentar over, hvis den ikke fanger din interesse.
-
Er holdt op med at tro og håbe..følger bare kursen faktuelt;-)
-
Det vil da være fedt hvis den lukker over 2900:-)
-
@StockBull forudsagde kurs 2968 den 18. november - ligner da en realistisk mulighed. Hans graf viste historisk tilbage til samme mønster over tid - så da baseret på kursfakta i mønstret.
-
Merus presented first data on their EGFR and c-MET bispecific ; judging solely from the stock price reaction , -17%, it doesn't seem to be a competitor for Amivantamab... https://ir.merus.nl/news-releases/news-release-details/merus-presents-first-human-data-mcla-129-34th-eortcnciaacr-ena
-
2900 i luk må vente til i morgen:-)
-
Exelixis also presented data on their TF ADC and probably not that impressive so far ....https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-promising-initial-dose-escalation-results
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind